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Objectives The purpose of this study was to define the incidence and predictors of implantable cardioverter-defibrillator
(ICD) therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) after place-
ment of an ICD for primary prevention.
Background Patients with a diagnosis of ARVD/C often receive an ICD for prevention of sudden cardiac death.
Methods Patients (n  84) from the Johns Hopkins registry with definite or probable ARVD/C who underwent ICD implan-
tation for primary prevention were studied. Detailed phenotypic, genotype, and ICD event information was ob-
tained and appropriate ICD therapies were adjudicated based on intracardiac electrograms.
Results Over a mean follow-up of 4.7  3.4 years, appropriate ICD therapy was seen in 40 patients (48%), of whom 16 (19%)
received interventions for potentially fatal ventricular fibrillation/flutter episodes. Proband status (p  0.001), induc-
ibility at electrophysiologic study (p  0.005), presence of nonsustained ventricular tachycardia (p  0 .001), and
Holter premature ventricular complex count 1,000/24 h (p  0.024) were identified as significant predictors of ap-
propriate ICD therapy. The 5-year survival free of appropriate ICD therapy for patients with 1, 2, 3, and 4 risk factors
was 100%, 83%, 21%, and 15%, respectively. Inducibility at electrophysiologic study (hazard ratio: 4.5, 95% confi-
dence interval: 1.4 to 15, p  0.013) and nonsustained ventricular tachycardia (hazard ratio: 10.5, 95% confidence
interval: 2.4 to 46.2, p  0.002) remained as significant predictors on multivariable analysis.
Conclusions Nearly one-half of the ARVD/C patients with primary prevention ICD implantation experience appropriate ICD
interventions. Inducibility at electrophysiologic study and nonsustained ventricular tachycardia are independent
strong predictors of appropriate ICD therapy. An increase in ventricular ectopy burden was associated with pro-
gressively lower event-free (appropriate ICD interventions) survival. Incremental risk of ventricular arrhythmias
and ICD therapy was observed with the presence of multiple risk factors. (J Am Coll Cardiol 2011;58:
1485–96) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.043Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is an inherited cardiomyopathy characterized
predominantly by ventricular arrhythmias, increased risk of
From the Division of Cardiology, The Johns Hopkins University School of Medicine,
Baltimore, Maryland. Funding for this study has been received from the National
Heart, Lung, and Blood Institute (K23HL093350 to Dr. Tandri), the St. Jude
Medical Foundation, Medtronic Inc., and Boston Scientific Corp. The Johns
Hopkins ARVD/C Program is supported by the Bogle Foundation, the Healing
Hearts Foundation, the Campanella family, and Wilmerding Endowments, and
the Dr. Francis P. Chiaramonte Private Foundation. Dr. Dalal is an employee ofsudden cardiac death (SCD), and right ventricular dysfunc-
tion (1–3). After a diagnosis of ARVD/C is established, the
most important management decision is whether to implant
Genentech Inc. Dr. Tedford has received a Fellow’s Travel Grant from Medtronic.
Dr. Calkins receives research support from Boston Scientific Corp., Medtronic Inc.,
and St. Jude Medical Foundation and is a consultant for Medtronic Inc. All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose.Manuscript received April 6, 2011; revised manuscript received June 9, 2011,
accepted June 27, 2011.
m
i
c
I
1486 Bhonsale et al. JACC Vol. 58, No. 14, 2011
Prophylactic ICD for Primary Prevention in ARVD/C September 27, 2011:1485–96an implantable cardioverter-
defibrillator (ICD) for treatment
of sustained ventricular arrhyth-
mias and prevention of SCD.
This is a critically important de-
cision because these are young
patients with few or no symp-
toms who are expected to live
many years with a device that is
not complication free. It is now
standard practice for ARVD/C
patients presenting with sus-
tained ventricular tachycardia
(VT) and/or ventricular fibrilla-
tion (VF) to undergo placement
of an ICD because of a high risk
of recurrent VT and/or SCD
(4–6). In contrast, there is much
more uncertainty regarding which
patients who have not had a pre-
vious sustained ventricular ar-
rhythmia should have an ICD
placed for primary prevention (7).
The objectives of this study
were 3-fold. First, we sought to
better define the incidence of
appropriate ICD therapy as well
as potential lifesaving therapy
against VF/ventricular flutter
(VFL) in patients with definite or probable ARVD/C
undergoing ICD implantation for primary prevention. Sec-
ond, we sought to identify which clinical and electrophysi-
ologic factors best identify patients at highest risk of
sustained VT or sudden death. Third, we sought to identify
a subgroup of patients with definite or probable ARVD/C
who are at sufficiently low risk that placement of an ICD as
part of a primary prevention strategy may not be needed.
We relied on the 2010 Task Force Criteria (TFC) (8) to
establish the diagnosis of ARVD/C. Particular attention
was focused on determining the influence of genotype,
incremental role of multiple risk factors, as well as the
relative risk of probands versus family members in the
development of sustained ventricular arrhythmia.
Methods
Patient population and follow-up. The Johns Hopkins
ARVD/C Program was established in 1995 to provide
clinical care for patients with ARVD/C and to study this
disease. All those in the registry who had implantation of an
ICD for primary prevention of sudden death, a follow-up
period of at least 2 months after implantation of the device,
and documentation of clinical outcomes were included in
the study. All subjects gave written informed consent to
participate in this study, which was approved by The Johns
Abbreviations
and Acronyms
ARVD/C  arrhythmogenic
right ventricular
dysplasia/cardiomyopathy
CI  confidence interval
CL  cycle length
EPS  electrophysiologic
study
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
NPV  negative predictive
value
NSVT  nonsustained
ventricular tachycardia
PPV  positive predictive
value
PVC  premature
ventricular complex
SCD  sudden cardiac
death
TFC  Task Force Criteria
VF  ventricular fibrillation
VFL  ventricular flutter
VT  ventricular
tachycardiaHopkins School of Medicine Institutional Review Board. eDetailed clinical information regarding demographics,
symptoms, electrocardiographic abnormalities on a 12-lead
electrocardiogram, signal-averaged electrocardiographic
testing, 24-h Holter monitoring, exercise stress testing, and
arrhythmia occurrence was obtained for each patient. Echo-
cardiographic and magnetic resonance imaging reports were
obtained, and images were reviewed for structural abnor-
malities to determine the severity and extent of right
ventricular dysfunction. Right ventricular angiography
and/or endomyocardial biopsy were performed per the
discretion of the managing cardiologist. Programmed ven-
tricular stimulation was performed according to each refer-
ring institution’s protocol. Electrophysiologic study (EPS)
was deemed inducible if a sustained ventricular tachyar-
rhythmia—VT or VF that lasted 30 s or required termi-
nation because of hemodynamic compromise was induced.
A detailed family history was obtained through patient
interview for pedigree analysis, and comprehensive desmo-
somal mutation testing was performed for those patients
whose DNA sample was available (9).
Patients were followed at yearly intervals as part of the
Johns Hopkins registry, and data including invasive and
noninvasive investigations, pedigree, device interrogation,
and stored electrograms were obtained from referring insti-
tutions and individual patients throughout the duration of
follow-up. In patients without an ICD intervention,
follow-up was to the date of death, transplantation, or most
recent follow-up evaluation, whichever came first. Of the 84
study patients, 28 were included in an earlier investigation
(10) and are reported with extended follow–up.
Diagnosis of ARVD/C. The diagnosis of ARVD/C is
based on the presence of major and minor diagnostic criteria
according to the 2010 revised TFC (8). The patients were
classified as having a diagnosis of definite ARVD/C when
they met the full criteria (2 major criteria or 1 major
criterion plus 2 minor criteria or 4 minor criteria). Probable
ARVD/C was considered present when only partial fulfill-
ment of the criteria was met (i.e., 1 major and 1 minor or 3
minor). Each of the patients with probable ARVD/C in this
study had received an ICD after diagnosis of ARVD/C by
their primary cardiologist and/or electrophysiologist.
ICDs and classification of discharges. All patients re-
ceived multifunctional third- or fourth-generation ICDs
between May 1995 and June 2010. Decisions regarding
ICD implantation were made by the managing cardiovas-
cular specialists. Stored intracardiac electrograms were an-
alyzed to classify arrhythmias responsible for precipitating
defibrillator discharges, according to following definitions
(11). VF or VFL was defined as an irregular or regular
tachycardia with a mean cycle length (CL) of 240 ms. VT
was defined as a regular tachycardia with mean CL 240
s. Defibrillator shocks were considered appropriate versus
nappropriate on the basis of standard criteria (2). When
omplete ICD interrogation information was not available,
CD interrogation interpretation by the outside referring
lectrophysiologist was used to classify arrhythmic events.
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onsciousness and postural tone with spontaneous recovery.
or purposes of our analysis, the term syncope was not used
f the clinical characteristics of a patient’s syncopal episode
ere suggestive of reflex-mediated or vasodepressor syn-
ope. Although we considered referring to this type of
yncope as cardiac syncope, we preferred to use the term
yncope and clarify this important distinction in the defini-
ions section. Nonsustained ventricular tachycardia (NSVT)
as defined as 3 consecutive ventricular premature beats
ith a rate 100 beats/min, lasting 30 s, which was
documented during exercise testing, loop monitoring, or
24-h Holter monitoring. Electrical or VT storm was defined
as the occurrence of VT or VF that resulted in 3 ICD
interventions (shock or antitachycardia pacing) in a 24-h
period (12).
Survival data and statistical analyses. Continuous vari-
ables are summarized as either mean  SD or median
(interquartile range) and compared across groups using a
t test or Mann-Whitney U test. Categorical variables are
reported as frequency (percentage) and compared between
groups by the chi-square or Fisher exact test. The cumula-
tive probability of survival free of appropriate ICD inter-
vention was determined by the Kaplan-Meier method, and
differences in survival between groups evaluated with the
log-rank test. Univariate Cox regression analysis identified
baseline variables that were significantly associated with
appropriate ICD therapy. Significantly associated variables
Baseline Clinical Characteristics of the Study PopulationTable 1 Baseline Clinical Characteristics of the Study Populati
Clinical Variable
Overall Population
(N  84)
Age at presentation, yrs 31.9 11.9
Male 39 (46)
Follow-up, yrs 4.73 3.39
Symptomatic at presentation 64 (76)
Dyspnea 9 (11)
Syncope 23 (27)
Pre-syncope 29 (35)
Palpitations 40 (48)
Chest pain 14 (17)
Other symptoms 20 (24)
Proband 54 (64)
Inducibility at EPS 40/72 (56)
NSVT 41 (49)
Desmosomal mutations (n  63) 36/63 (57)
LV dysfunction 12 (14)
T-wave inversion in V1 to V3 55/81 (68)
PVCs on Holter monitoring before ICD implantation 1,977 (4,699)
Late potentials on SAECG 33/53 (62)
PVCs 1,000/24 h on Holter monitoring 39/62 (63)
Major RV structural abnormality 24 (29)
FH of sudden death due to suspected ARVD/C 14 (17)
Definite ARVD/C per 2010 TFC 70 (83)
Values are mean  SD, n (%), or n/N (%).
ARVD/C arrhythmogenic right ventricular dysplasia/cardiomyopathy; EPS  electrophysiologic study
left ventricular; NSVT  nonsustained ventricular tachycardia; PVC  premature ventricular complex; RV(p  0.15) were integrated into multivariable analysis using
the Cox proportional hazard model to identify independent
predictors of appropriate ICD intervention. All analyses
were performed using PASW statistics version 18.0 (SPSS
Inc., Chicago, Illinois). A p value 0.05 was considered
significant.
Results
Patient population. The patient population consisted of
84 ARVD/C patients who received an ICD for primary
prevention of SCD. Seventy patients met the revised TFC
(8) for ARVD/C and received a diagnosis of definite
ARVD/C, and 14 patients received a diagnosis of probable
ARVD/C. The mean age at presentation was 31.9  11.9
years (range 11 to 59 years) (Table 1), with two thirds of the
cohort being younger than 40 years at initial evaluation.
Thirty-nine patients (46%) were males. Fifty-four patients
(64%) were probands (an affected person ascertained inde-
pendently of family history of ARVD/C), whereas the rest
were family members (affected individuals ascertained
through family screening).
Genetic testing was performed in 63 patients, and patho-
genic desmosomal mutations were detected in 36 (43%). An
EPS was performed in 72 patients before ICD implanta-
tion, and inducibility of sustained VT/VF was observed in
40 patients (48%). The mean CL of the induced VT was
257 54 ms (range 170 to 404 ms). Holter monitoring was
Appropriate ICD Therapy
(n  40)
No Appropriate ICD Therapy
(n  44) p Value
32 11.1 31.7 12.6 0.916
20 (50) 19 (43) 0.531
5.96 3.52 3.61 2.88 0.001
36 (90) 28 (64) 0.005
7 (17.5) 2 (4.5) 0.079
10 (25) 13 (30) 0.641
17 (42.5) 12 (27) 0.143
23 (57.5) 17 (39) 0.084
6 (15) 8 (18) 0.696
10 (25) 10 (23) 0.807
36 (90) 18 (41) 0.001
26/34 (76) 14/38 (37) 0.001
28 (70) 13 (30) 0.001
16/33 (48) 20/30 (67) 0.145
7 (18) 5 (11) 0.422
27/37 (73) 28 (64) 0.370
4,397 (6,274) 1,027 (2,728) 0.001
14/23 (61) 19/30 (63) 0.854
20/25 (80) 19/37 (51) 0.022
13 (33) 11 (25) 0.744
5 (13) 9 (21) 0.329
32 (80) 38 (86) 0.434on; FH family history; ICD implantable cardioverter-defibrillator; IQR interquartile range; LV
 right ventricular; SAECG  signal-averaged electrocardiogram; TFC  Task Force Criteria.
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Prophylactic ICD for Primary Prevention in ARVD/C September 27, 2011:1485–96performed in 65 patients and 1,000 premature ventricular
omplexes (PVCs)/24 h were seen in 39 (60%). NSVT on
xercise stress testing, Holter monitoring, or loop monitors
as seen in 41 patients (49%). At the time of ICD implan-
tation, one third of the patients were using beta-blockers with
3 (4%) receiving antiarrhythmic agents (Table 2). No signifi-
cant phenotypic or outcome differences were observed between
those with and without the testing (Online Tables 1 to 3).
ICD implantation. A single-chamber device was im-
planted in 56 patients (67%) and a dual-chamber device in
28 patients (33%). The mean age at ICD implantation was
35.1  11.4 years (range 13 to 59 years) (Fig. 1A). The
mean R-wave amplitude was 9.4  4.9 mV (range 3 to 30
mV), with 12 patients exhibiting R-wave amplitudes 5
mV (range 3 to 4.8 mV). Appropriate sensing was achieved
in all patients at the time of device implantation. The mean
defibrillation threshold was 15.7  6.5 J (range 5 to 35 J).
Twenty patients (24%) had device-related complications
during long-term follow-up including pocket hematoma
(n 2), pocket infection (n 1), lead dislodgment (n 2),
ubclavian vein occlusion (n 2), lead fracture (n 1), lead
evision (n  4), lead recall (n  3), lead replacement due
o sensing problem (n  3), generator explantation due to
nfection (n  1), and dual-chamber upgrade due to
onduction abnormalities (n  1).
CD therapy and follow-up. Over a mean follow-up of
.7  3.4 years, 40 (48%) of the 84 patients with definite or
robable ARVD/C had received appropriate ICD therapy.
he mean CL of the arrhythmia at the first appropriate
vent was 265 35 ms (range 210 to 360 ms). Patients with
diagnosis of probable ARVD/C experienced appropriate
CD interventions in comparable proportion to those with
definite diagnosis (8) (46% vs. 57%; p  0.434). The
edian time from ICD implantation to first appropriate
herapy was 0.54 years (range 0.02 to 5.4 years). The
ajority (55%) of appropriate interventions occurred within
year of ICD implantation; however, 6 patients (7%) had
nitial therapy 3 or more years after implantation (Fig. 1B).
he median number of appropriate ICD intervention dur-
ng follow-up was 5.5 (range 1 to 72), with 1 patient
eceiving 50 interventions (Fig. 1C). Twenty-five patients
63%) were engaged in exertional or recreational activity at
he time of first appropriate shock, whereas 10 (25%) were
edentary. VT storms were seen in 16 patients (19%) with
0 (12%) having 1 VT storm, 4 (5%) having 2 episodes, and
(2%) experiencing 3 storm episodes. The mean duration
rom ICD implantation to the first VT storm was 3.4  2.6
ears (range 0.18 to 10.6 years).
Overall, the cumulative survival free of appropriate ICD
herapy was 73%, 64%, 42%, and 37%, respectively at 1, 2,
, and 10 years of follow-up (Fig. 2A). The average yearly
ate of appropriate ICD interventions for the overall pop-
lation was 10%. Probands demonstrated a higher event rate
13%/year) compared with family members (3.4%/year). On
aplan-Meier analysis, no significant event-free survival
ifference was detected between definite and probable pa- M
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September 27, 2011:1485–96 Prophylactic ICD for Primary Prevention in ARVD/Ctients. Patients with appropriate ICD interventions had
significantly longer follow-up (5.9  3.5 years vs. 3.6  2.9
years; p  0.001), were more often symptomatic at presen-
tation (90% vs. 64%; p  0.005), and had a higher median
Figure 1 Prophylactic ICD Implantation in Arrhythmogenic Righ
(A) Age at time of defibrillator implantation. (B) Interval between implantable card
(C) Number of appropriate ICD discharges.PVC burden on Holter monitoring (4,397 vs. 1,027; p 0.001). Inappropriate shocks were seen in 20 patients (24%).
The median time to first inappropriate shock was 1.3 years
(range 0.09 to 9.13 years). One third of these events
occurred within 1 year of ICD implantation, with 89%
tricular Dysplasia/Cardiomyopathy Patients
r-defibrillator (ICD) implantation and the first appropriate discharge.t Ven
ioverteoccurring within 5 years of implantation. The inappropriate
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Prophylactic ICD for Primary Prevention in ARVD/C September 27, 2011:1485–96discharges were due to sinus tachycardia (n  8), another
type of supraventricular arrhythmia (n  5), and electrical
oise (n  2) due to lead problems.
An appropriate ICD intervention for VF/VFL was seen
n 16 patients (19%), of whom probands constituted 15
94%) and 1 patient was a family member (p  0.001). The
ean CL of the first VF/VFL episode was 222  13 ms
range 200 to 240 ms), and the median duration between
mplantation and first ICD intervention triggered by VF/
FL was 1.5 years (range 0.05 to 7 years). The cumulative
urvival free of appropriate ICD therapy for VF/VFL was
Figure 2 Appropriate ICD Therapy in Arrhythmogenic
Right Ventricular Dysplasia/Cardiomyopathy Patients
(A) Kaplan-Meier analysis of cumulative survival from any appropriate implant-
able cardioverter-defibrillator (ICD) interventions. (B) Kaplan-Meier analysis of
survival free of ventricular fibrillation/ventricular flutter (VF/VFL).3%, 87%, 79%, and 68% at 1, 2, 5, and 10 years, trespectively (Fig. 2B). The average rate of ICD interven-
tions for VF/VFL was 4%/year. The estimated mortality
reduction at 1, 5, and 10 years of follow-up was 6%, 18%,
and 29% (i.e., the difference between actual patient survival
rate of 99%, 97%, and 97%, respectively, at those times and
comparable VF/VFL-free survival).
Forty-four patients (52%) had no ICD interventions. At
last follow-up, 82 patients (98%) were alive, 1 patient died
of a brain tumor, and another died of complications after a
heart transplantation. Seven patients underwent heart trans-
plantation due to progressive heart failure and/or incessant
arrhythmias. The mean duration from ICD implantation to
transplantation was 6.8 4.1 years (range 1.5 to 13.2 years).
Predictors of appropriate ICD therapy. Shown in Table 3
are the variables analyzed as potential predictors of appro-
priate ICD interventions. Univariate predictors of appropri-
ate ICD therapy were proband status (hazard ratio [HR]:
6.4; 95% confidence interval [CI]: 2.3 to 18.2; p  0.001),
the presence of NSVT (HR: 3.8; 95% CI: 1.9 to 7.6; p 
.001), inducibility at EPS (HR: 3.1; 95% CI: 1.4 to 6.9;
 0.005), and Holter PVC count 1,000/24 h (HR: 3.1;
5% CI: 1.1 to 8.3; p  0.024). NSVT (HR: 10.54; 95%
I: 2.40 to 46.18; p  0.002) and inducibility at EPS (HR:
.5; 95% CI: 1.37 to 14.96; p  0.013) alone remained as
ignificant predictors of appropriate ICD interventions on
ultivariable analysis. Shown in Figure 3 is the Kaplan-
eier analysis of freedom from any appropriate ICD
ntervention stratified by inducibility at EPS, NSVT, PVCs
1,000 on 24-h Holter monitoring, and proband status.
he positive predictive value (PPV) and the negative pre-
ictive value (NPV) of EPS inducibility were 65% and 75%,
espectively, for appropriate ICD therapy. In probands, the
PV increased to 73%, whereas in family members, an NPV
f 88% was seen. Also, the cumulative survival rate free of
ppropriate ICD therapy at 10 years was significantly higher
64%) in those noninducible at EPS compared with those
nducible (23%). Among inducible patients, 10 (25%) expe-
ienced appropriate ICD interventions for VF/VFL,
hereas only 1 of the 32 noninducible patients (3%) had
uch ICD therapy for VF/VFL, providing a high NPV of
7%. None of the 18 family members with negative findings
n EPS in our study experienced a VF/VFL episode.
The presence of NSVT had a sensitivity, specificity, PPV,
nd NPV of 70%, 70%, 68%, and 72%, respectively, for
ppropriate ICD therapy. Among family members, the
PV was 95%, with only 1 of the 20 patients without
SVT experiencing an appropriate shock. None of the 13
amily members with a PVC count 1,000/24 h received
ppropriate ICD therapy, providing this criterion with an
PV of 100%. As shown in Figure 4, a higher PVC burden
n Holter monitoring was associated with an increasing
roportion of patients experiencing appropriate ICD inter-
entions and a lower cumulative event-free survival rate.
elationship between the number of risk factors and
ppropriate ICD therapy. Fifty-four patients had evalua-
ion of all 4 major risk factors identified (inducibility at
1491JACC Vol. 58, No. 14, 2011 Bhonsale et al.
September 27, 2011:1485–96 Prophylactic ICD for Primary Prevention in ARVD/CEPS, NSVT, Holter monitoring PVC count 1,000/ 24 h,
and proband status). The numbers of patients with 0, 1, 2,
3, and 4 risk factors were 7 (8%), 8 (10%), 13 (16%), 17
(20%), and 9 (11%), respectively. Appropriate ICD therapy
occurred in 0 (0%), 0 (0%), 3 (23%), 11 (65%), and 7 (78%)
patients in each group, respectively. Patients with no or 1
risk factor had no events, and patients with multiple risk
factors had a substantially increased risk of appropriate ICD
therapy (Fig. 5). The 5-year survival rate free of appropriate
ICD therapy for patients with 1, 2, 3, and 4 risk factors was
100%, 83%, 21%, and 15%, respectively.
Discussion
Main findings. This study reports the outcome of a large
North American cohort of 84 patients with definite or
probable ARVD/C who received ICD implantation for
primary prevention of SCD. This study has 4 main findings.
First, the results of this study reveal a high rate of appro-
priate ICD therapy in this patient population. Nearly one-
half of the patients experienced appropriate ICD therapy
with one fifth receiving potentially lifesaving therapy for
VF/VFL during an average of 4.7 years of follow-up. Second,
our study identifies clinical variables: inducibility at EPS,
the presence of NSVT, proband status, and Holter moni-
toring PVC count 1,000/24 h as significant predictors of
appropriate ICD therapy. Third, the results of this study
show that the presence of multiple risk factors incrementally
increases the likelihood of appropriate ICD therapy with
mutation status, electrocardiographic and major structural
abnormalities not affecting this risk. Patients, especially
family members with none of these markers, appear to be at
low risk of life-threatening ventricular arrhythmias. Finally,
Predictors of Appropriate ICD InterventionTable 3 Predictors of Appropriate ICD Intervention
Variable
Univ
HR
Proband status 6.48 2.
NSVT 3.83 1.
Inducibility at EPS 3.13 1.
PVCs 1,000/24 h on Holter monitoring 3.12 1.
Major depolarization criteria 1.48 0.
LV dysfunction 1.28 0.
T-wave inversion (V1-V3) 1.12 0.
Late potentials on SAECG 1.06 0.
Female 1.05 0.
Age 30 yrs at presentation 1.04 0.
Medication use at ICD implantation 0.99 0.
History of syncope 0.91 0.
Major RV structural abnormality 0.87 0.
Presence of inappropriate shock 0.86 0.
FH of sudden death 35 yrs due to suspected ARVD/C 0.70 0.
Presence of pathogenic mutation 0.59 0.
Definite classification per 2010 TFC 0.58 0.
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.this investigation reveals that an increase in ventricularectopy burden is associated with progressively increasing
risk of appropriate ICD interventions and a lower event-free
survival rate.
Previous reports. ARVD/C is an uncommon but impor-
tant cause of SCD because most of these individuals are
young. It is estimated that it accounts for one fifth of all
episodes of SCD that occur in patients younger than the
age of 35 years (13). During the past decade, 4 studies,
predominantly in patients with sustained VT/VF, have
demonstrated the efficacy of ICD therapy and its impact
on SCD prevention. These studies have included, in
varying proportions (7% to 73%), primary prevention
patients with overall rates of ICD therapy ranging from
48% to 70% (4 – 6,14). Similar rates of appropriate (14)
and lifesaving therapy (10) in patients receiving ICDs for
primary and secondary prevention indications have been
reported, underscoring the considerable potential ar-
rhythmic risk among recipients of prophylactic ICD.
Only 1 recent study of largely European patients exam-
ined the role of prophylactic ICD therapy in primary
prevention of SCD (15). In this study by Corrado et al.
(15), 106 ARVD/C patients without previous sustained
VT or VF were studied over a mean follow-up of 58
months. Twenty-five patients (24%) had appropriate
ICD interventions, and 17 (16%) experienced shocks for
life-threatening VF or VFL, with syncope emerging as
the sole predictor of ICD therapy. Taken together, these
studies suggest that ICD therapy has an important role in
the primary prevention of SCD in patients with
ARVD/C.
VT/VF in ARVD/C. The results of the present study
confirm and extend the results of these previous investiga-
Analysis Multivariable Analysis
CI p Value HR 95% CI p Value
.23 0.001 1.62 0.30–8.59 0.574
1 0.001 10.54 2.40–46.19 0.002
1 0.005 4.52 1.37–14.96 0.013
5 0.024 3.48 0.72–16.98 0.123
4 0.533
0 0.552
2 0.758
5 0.896
7 0.878
3 0.906
3 0.976
7 0.799
7 0.826
7 0.686
6 0.417
6 0.125 0.44 0.14–1.40 0.165
6 0.167ariable
95%
30–18
92–7.6
41–6.9
16–8.3
43–5.1
57–2.9
54–2.3
46–2.4
56–1.9
56–1.9
51–1.9
45–1.8
25–3.0
42–1.7
29–1.6
29–1.1
26–1.2tions. In our study, over approximately 5 years of follow-up,
a
p
c
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Prophylactic ICD for Primary Prevention in ARVD/C September 27, 2011:1485–96appropriate ICD therapy was observed in nearly one-half of
the study patients. This high cumulative incidence of appro-
priate ICD interventions likely reflects the clinical charac-
teristics of the population (probands vs. family members),
minimal prophylactic use of antiarrhythmic agents and
beta-blockers, and the intrinsic arrhythmic potential among
ARVD/C patients. As in the study by Corrado et al. (15),
the estimate of the potential survival benefit of ICD was
limited to appropriate ICD therapies for episodes of VF/
Follow up (years)
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No
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Figure 3 Risk Factors for Appropriate ICD Therapy
Cumulative rate of first appropriate discharge stratified according to inducibility at
nonsustained ventricular tachycardia (NSVT) (B), premature ventricular complex (PVFL. In our study, appropriate therapy for VF/VFL wasseen in nearly one-fifth of the patients, with an estimated
survival benefit of 19% seen at 5 years of follow-up. This
was similar to the 23% reduction seen by Corrado et al. (15)
nd comparable to that observed in large ICD primary
revention studies for CAD like the MADIT-II (Multi-
enter Automatic Defibrillator Implantation Trial) (16)
(28%, 2 years) and SCD-Heft (Sudden Cardiac Death in
Heart Failure Trial) (16) (23%, 5 years). The annual rate of
appropriate therapy for VF/VFL in our study was 4%,
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September 27, 2011:1485–96 Prophylactic ICD for Primary Prevention in ARVD/CCorrado et al. (15), confirming the lifesaving efficacy of
prophylactic ICD therapy.
Predictors of appropriate ICD therapy. INDUCIBILITY AT EPS.
The results of our study show that inducibility at EPS is a
significant, strong predictor of appropriate ICD therapy in
primary prevention ARVD/C patients with a significantly
worse event-free survival rate in those inducible. Addition-
ally, its NPV is considerable, especially in family members.
In contrast, in the study by Corrado et al. (15), EPS
inducibility did not seem to affect the risk in the survival
analysis and provided a 35% PPV and a 70% NPV. A higher
Figure 4 Holter Monitoring and ICD Therapy
(A) Relationship between the number of patients experiencing appropriate implant
increasing premature ventricular complex (PVC) count into equal pentiles. (B) Cum
fied according to increasing PVC count and unadjusted hazard ratio (HR) for theseevent rate among our study population as well as populationcharacteristics unique to each study could potentially explain
this difference. We do recognize that the predictive value
(both positive and negative) of this test is not perfect and
that a certain proportion experienced ICD interventions
even with a test with negative findings. However, our study
shows that multiple factors contribute to the occurrence of
arrhythmias in ARVD/C patients and that EPS inducibility
contributes to their overall risk assessment. Most impor-
tantly, EPS inducibility when used in conjunction with
other risk factors and as part of an additive scheme as
proposed in this paper can provide considerable prognostic
ardioverter-defibrillator (ICD) therapy and patient groups stratified according to
survival free of appropriate ICD therapy among patient groups (pentiles) strati-
t groups demonstrating progressively increasing risk with worsening PVC burden.able c
ulative
patieninformation for the physician.
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Prophylactic ICD for Primary Prevention in ARVD/C September 27, 2011:1485–96NSVT. In the study by Corrado et al. (15), asymptomatic
patients with NSVT presented a trend toward an increased
arrhythmic risk and NSVT reached borderline significance
as a predictor of appropriate ICD therapy. They had an
overall rate of appropriate ICD intervention of 3.7%/year
Figure 5 Incremental Risk of Appropriate
ICD Therapy With Multiple Risk Factors
Cumulative survival free of appropriate implantable cardioverter-defibrillator
(ICD) therapy (A) and ICD therapy for VF/VFL (B) stratified by the number of
risk factors (the risk factors considered are inducibility at electrophysiologic
study, the presence of nonsustained ventricular tachycardia, Holter premature
ventricular complex count 1,000/24 h, and proband status).and a rate of appropriate ICD intervention against VF/VFL uof 1.48%/year. In our study, NSVT was identified as an
independent predictor of appropriate ICD therapy. Patients
with NSVT had somewhat higher (6%/year) appropriate
discharge rate and a 2%/year VF/VFL rate. The presence of
NSVT was associated with a higher cumulative appropriate
shock rate in both probands (p  0.034) and family
members (p 0.009) and in both older (older than 30 years;
p  0.006) and younger (younger than 30 years; p  0.002)
patients, implying a comprehensive prognostic role for the
presence of NSVT in clinical situations. In nonischemic as
well as ischemic cardiomyopathies, NSVT has similarly
been seen to be an independent predictor of appropriate
ICD therapy (17). In hypertrophic cardiomyopathy, NSVT
has also proved to be a significant independent risk factor
for SCD, especially in the young (18).
PROBAND STATUS. In our study, proband status was a
predictor of appropriate ICD therapy. Thirty-six probands
(90%) had appropriate ICD intervention compared with
only 4 family members (9%) who received ICD therapy. Of
the 4 family members with appropriate ICD therapy, 1 had
EPS inducibility, whereas the other 3 had the presence of
NSVT and/or PVC count 1,000/24 h on Holter moni-
toring. All had pathogenic mutations and were phenotyped
definite per new TFC (8). Only 1 family member experi-
enced appropriate therapy for VF/VFL during the follow-
up. This was a 45-year-old asymptomatic Caucasian male
with PKP-2 mutation who had an ICD implanted due to
family history of ARVD/C in his brother and abnormal
findings on magnetic resonance imaging demonstrating
major structural abnormalities with NSVT and substantial
PVCs (2,505) on 24-h Holter monitoring. Within 6
months of ICD implantation, he experienced an appropriate
shock (CL 240 ms) while exercising. This observation is
consistent with the recent finding by Corrado et al. (15) and
previous large family studies (19) in which probands have
shown considerable arrhythmic and symptom manifesta-
tion, whereas the majority of affected ARVD/C relatives are
likely to have a benign course. In our study, no family
member experienced any VT storm, underwent cardiac
transplantation, or died.
VENTRICULAR ECTOPY. Our study identified that a Holter
onitoring PVC count 1,000/24 h was significantly
ssociated with higher cumulative ICD therapy. Uniquely,
he proportion of patients receiving appropriate ICD ther-
py increased progressively with increasing PVC burden.
atients with a higher PVC count had a significantly lower
vent-free survival rate and increased probability of appro-
riate ICD therapy. The prognostic role of frequent ven-
ricular ectopy in predicting SCD although a new concept in
RVD/C, has been seen in large coronary artery disease
rials and nonischemic cardiomyopathy as well, providing
vidence of its potential role (20). Our data suggest that this
requent manifestation of ARVD/C may be a marker for
lectrical instability culminating in more malignant ventric-
lar arrhythmias over time.
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physiologic characteristics in predicting appropriate ICD
interventions in ARVD/C patients has been unclear. As a
result, the criteria for optimal selection of ARVD/C pa-
tients who will benefit from prophylactic ICD implantation
are undefined. The results of the present study provide new
insight into risk stratification of ARVD/C patients before
ICD implantation for primary prevention of SCD. The
presence a proband status, 1,000 PVCs, NSVT, and
inducible VT at EPS identified ARVD/C individuals at
high risk of appropriate therapy. Assuming our findings are
confirmed by others, we propose that these risk factors be
referred to as the PONI (Proband status, more than One
thousand extrasystoles, Nonsustained VT and Inducible VT
at EPS) risk stratification scheme. Our study demonstrates
for the first time that a combination of these 4 risk factors
portends incremental risk and can be used to risk-stratify
patients. The presence of 2, 3, or 4 risk factors is associated
with an escalating ICD event rate. On the other hand,
ARVD/C patients with no or 1 risk factor did not receive
any appropriate ICD intervention during follow-up and
appear to be at very low risk of the development of a
sustained ventricular arrhythmia or SCD. Therefore, given
the concomitant risk of inappropriate shocks and lead-
related complications, these patients may not be candidates
for prophylactic ICD implantation. This additive risk factor
scheme is particularly significant for clinical management
and arrhythmic risk stratification of asymptomatic
ARVD/C relatives and genotype-positive family members
who may only manifest ventricular ectopy with minimal
ARVD/C phenotype.
In contrast to the study by Corrado et al. (15), a history
of syncope was seen less often (27% vs. 39%) in our cohort.
Also, unlike that study, the majority (75%) of patients
receiving appropriate ICD therapy did not have a history of
syncope. Despite these differences, nearly one-half of the
patients with syncope in our study experienced appropriate
ICD therapy at a comparably high rate (9%/year). Impor-
tantly, significantly more patients with recent unexplained
syncope (6 months before ICD implantation) experienced
ICD interventions than those with remote syncope (63% vs.
20%; p  0.046), none of whom experienced potentially
fatal VF/VFL. Our data suggest that absence of syncope
does not confer protection from the risk of appropriate ICD
therapy due to the presence of multiple other risk factors.
Furthermore, it did not emerge as an independent predictor
of ICD therapy. On the other hand, the presence of syncope
was associated with similar high rates of appropriate ICD
therapy, as seen in the study by Corrado et al. (15). More
importantly, a history of recent syncope suggests a higher
risk of ventricular arrhythmias and should prompt consid-
eration for ICD therapy.
Study limitations. There are several limitations to consider
when interpreting the results of this study. The survival
benefit of ICD therapy was assessed by assuming that
VF/VFL would have been fatal in all cases without shocktherapy. Because even very rapid ventricular tachyarrhyth-
mia may self-terminate before death, the use of appropriate
ICD shocks for VF/VFL as a surrogate for SCD may have
led to an overestimation of survival benefit from ICD.
These patients were clinically judged to have a high arrhyth-
mic risk to warrant prophylactic ICD therapy. Therefore,
the reported rate of arrhythmic events does not necessarily
correspond to the true arrhythmic risk of an unselected
general cohort of ARVD/C patients, which is likely char-
acterized by lower mortality rates (3,19). Second, we did not
have complete information on the CL of treated arrhyth-
mias in all patients. When intracardiac tracing were unavail-
able for review, we relied on the interpretation of the
treating electrophysiologist with regard to the appropriate-
ness of the ICD intervention. Third, not all patients had
EPS or Holter monitoring performed before ICD implan-
tation. This could potentially introduce bias due to missing
data and affect the precision of the HR estimates with
resultant wide CIs due to a reduced number during multi-
variable modeling. Nonetheless, we believe that our study
results and analysis indicate important clinically relevant
associations for arrhythmic risk stratification and manage-
ment of ARVD/C patients. Fourth, decisions about device
programming including VT detection were made at the
discretion of the patient’s clinical electrophysiologist. Last,
potentially lethal arrhythmic manifestations of ARVD/C
are often unpredictable, and a mean follow-up of half a decade
may not be enough to generalize predictions regarding the
low-risk nature of certain ARVD/C patients to their entire
lifetime. However, the observation that appropriate ICD
therapy is received early after implantation in high-risk
ARVD/C patients coupled with electrical quiescence of the
low-risk group during this period makes it plausible that
this reflects their long-term course.
Conclusions
This study represents an important step in understanding
the incidence of ICD interventions, identifying predictors
of appropriate ICD therapy, and developing a risk stratifi-
cation scheme in ARVD/C patients undergoing primary
prevention ICD implantation. Patients receiving ICD im-
plantation for primary prevention of SCD experience a
considerable amount of appropriate ICD interventions with
an appreciable estimated survival benefit. Probands are more
often symptomatic and are at higher arrhythmic risk than
family members, the majority of whom are asymptomatic
and at low risk of ICD therapy. Inducibility at EPS and the
presence of NSVT are independent predictors of appropri-
ate ICD therapy in this population. These markers coupled
with proband status and a high ventricular ectopy burden on
24-h Holter monitoring can be used to risk-stratify
ARVD/C patients before ICD implantation. Patients with
multiple risk factors are at considerable risk of future
appropriate ICD therapy and benefit from ICD implanta-
tion, whereas those with no or 1 risk factor may not be
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Prophylactic ICD for Primary Prevention in ARVD/C September 27, 2011:1485–96candidates. The results of this study combined with the
results of recently published study (15) add to the growing
evidence of ICD therapy in primary prevention of SCD in
ARVD/C patients. There exists a need for larger prospec-
tive studies of arrhythmic outcomes among ARVD/C
patients with prophylactic ICD to determine the long-term
validity of these predictive markers.
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